Patents by Inventor Eli LEWIS

Eli LEWIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240118792
    Abstract: A method for configuring a system having a wearable optical unit is disclosed. The method includes powering on the system, and in response to the system being powered on, using one or more processors to control the system to: determine whether to cause the system to run a configuration workflow, and in response to determining to cause the system to run the configuration workflow, (a) control the system in connection with configuring an interpupillary distance (IPD) for a user of the system, (b) determine whether the IPD is configured for the user, and (c) in response to determining that the IPD is configured for the user, control the system in connection with configuring a focus of the optical unit.
    Type: Application
    Filed: October 11, 2022
    Publication date: April 11, 2024
    Inventors: Trae Benjamin Stephens, Benjamin Eli Nelson Chelf, Nicholas Cory Johnson, John Aaron Boiles, Nicholas Grant Lewis, Kevin Robert McKinney, Steven David Oliver, Tun Yuen Yeung, Meghan Easley, Robin Porter, Jeremiah O'Leary, Keith Alsberg, Robert Samuel Clay
  • Publication number: 20190307866
    Abstract: The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition of alpha-1-antitrypsin.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 10, 2019
    Inventors: Ilana Nathan, Eli Lewis, Boris Khalfin
  • Patent number: 10086070
    Abstract: A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 2, 2018
    Assignee: Ben Gurion University of the Neger Research and Development Authority
    Inventor: Eli Lewis
  • Patent number: 9895420
    Abstract: The present invention provides a chimera protein made of amino acid residues derived from IL-1beta propeptide and the IL-1Ra mature peptide and polynucleotides encoding the protein. The present invention also provides usages of the protein and the polynucleotides in pharmaceutical compositions that treat inflammation.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: February 20, 2018
    Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN GURION UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Eli Lewis, Peleg Rider, Charles A. Dinarello
  • Publication number: 20170202961
    Abstract: A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Inventor: Eli LEWIS
  • Publication number: 20160220641
    Abstract: The present invention provides a chimera protein made of amino acid residues derived from IL-1beta propeptide and the IL-1Ra mature peptide and polynucleotides encoding the protein. The present invention also provides usages of the protein and the polynucleotides in pharmaceutical compositions that treat inflammation.
    Type: Application
    Filed: June 5, 2014
    Publication date: August 4, 2016
    Applicants: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. (BE N-GURION UNIVERSITY), THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Eli Lewis, Peleg Rider, Charles A. Dinarello
  • Publication number: 20150010581
    Abstract: The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (AAT) and temporary T-cell depletion including but not limited to anti-CD4 and anti-CD8 antibodies.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 8, 2015
    Inventor: Eli Lewis
  • Publication number: 20110237496
    Abstract: The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition of alpha-1-antitrypsin.
    Type: Application
    Filed: September 6, 2009
    Publication date: September 29, 2011
    Inventors: Ilana Nathan, Eli Lewis, Boris Khalfin
  • Publication number: 20110112017
    Abstract: Embodiments herein concern compositions and methods for treating diabetes in a subject.
    Type: Application
    Filed: June 11, 2010
    Publication date: May 12, 2011
    Inventors: Lee SHAPIRO, Charles A. DINARELLO, Eli LEWIS, Peter GOTTLIEB, Amy WALLACE, Aaron MICHELS, Gregory B. POTTS